Loading stock data…
FULC
$7.36+0.23 (+3.23%)
Market ClosedLast close May 1
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecules to improve the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Fulcrum Therapeutics, Inc. in the Healthcare sector is trading at $7.36. The stock is currently 53% below its 52-week high of $15.74, remaining 16.7% below its 200-day moving average. Technical signals show neutral RSI of 45 and bearish MACD signal, explaining why FULC maintains its current current market pressure. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 45) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$7.36
Potential Upside
5%
Whystock Fair Value$7.73
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus10 analysts
Buy
Mean target$18.80+155.4%
Range$7.00 – $25.00
Fundamentals
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecules to improve the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its clinical-stage produ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$539.46M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
3.27
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-20.98%
Volume
Today's trading volume
653,905
Recent News
Fulcrum Therapeutics Inc (FULC) Q1 2026 Earnings Call Highlights: Strategic Advances Amid ...
Despite increased R&D and administrative costs, Fulcrum Therapeutics Inc (FULC) showcases promising clinical progress and a robust financial outlook.
Fulcrum Therapeutics, Inc. Q1 2026 Earnings Call Summary
Moby summary of Fulcrum Therapeutics, Inc.'s Q1 2026 earnings call
Fulcrum Therapeutics Q1 Earnings Call Highlights
Fulcrum Therapeutics (NASDAQ:FULC) highlighted new clinical and corporate progress during its first-quarter 2026 financial results and business update call, with management emphasizing positive Phase 1b data for its lead sickle cell disease candidate, pociredir, and outlining next steps toward a pot
Fulcrum (FULC) Q1 2026 Earnings Transcript
The first quarter of 2026 was an important and exciting period for Fulcrum highlighted by the positive clinical data we reported from the Phase Ib PIONEER trial of Potero der in sickle cell disease. Now as a reminder, sickle cell disease is a serious genetic blood disorder with a significant unmet need, affecting approximately 120,000 patients in the United States and millions more globally. Patients with sickle cell disease face a substantial disease burden, including chronic pain and fatigue as well as serious complications, such as vaso-occlusive crises, stroke and progressive end organ damage, all of which result in a substantial reduction in life expectancy of over 20 years.
Fulcrum Therapeutics Shares Climb After Q1 Earnings Outperform Expectations
Fulcrum Therapeutics Inc. (NASDAQ:FULC) moved higher in pre-market trading on Monday after reporting first-quarter results that topped analyst expectations.